Vanda Pharmaceuticals Inc (NASDAQ: VNDA) stock jumped 0.85% on Monday to $3.58 against a previous-day closing price of $3.55. With 0.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.3 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.6750 whereas the lowest price it dropped to was $3.5100. The 52-week range on VNDA shows that it touched its highest point at $11.04 and its lowest point at $3.30 during that stretch. It currently has a 1-year price target of $4.25. Beta for the stock currently stands at 0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VNDA was up-trending over the past week, with a rise of 4.99%, but this was down by -17.51% over a month. Three-month performance dropped to -39.73% while six-month performance fell -42.26%. The stock lost -66.29% in the past year, while it has lost -51.56% so far this year. A look at the trailing 12-month EPS for VNDA yields 0.21 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.09. This implies an EPS growth rate of -109.09% for this year and -4500.00% for next year.
Float and Shares Shorts:
At present, 56.78 million VNDA shares are outstanding with a float of 55.58 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.68 million, which was 2.93% higher than short shares on Sep 28, 2023. In addition to Dr. Mihael H. Polymeropoulos M.D. as the firm’s Founder, President, CEO & Chairman of The Board, Mr. Kevin Patrick Moran serves as its Senior VP, CFO & Treasurer.
Through their ownership of 104.51% of VNDA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.16% of VNDA, in contrast to 34.98% held by mutual funds. Shares owned by individuals account for 32.42%. As the largest shareholder in VNDA with 8.66% of the stake, BlackRock Fund Advisors holds 4,978,834 shares worth 4,978,834. A second-largest stockholder of VNDA, The Vanguard Group, Inc., holds 3,333,134 shares, controlling over 5.80% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in VNDA, holding 3,266,025 shares or 5.68% stake. With a 3.00% stake in VNDA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,722,130 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.41% of VNDA stock, is the second-largest Mutual Fund holder. It holds 1,388,129 shares valued at 6.08 million. Vanguard Extended Market Index Fu holds 1.51% of the stake in VNDA, owning 870,631 shares worth 3.81 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VNDA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With VNDA analysts setting a high price target of $4.25 and a low target of $4.25, the average target price over the next 12 months is $4.25. Based on these targets, VNDA could surge 18.72% to reach the target high and rise by 18.72% to reach the target low. Reaching the average price target will result in a growth of 18.72% from current levels.
Summary of Insider Activity:
Insiders traded VNDA stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 3,724 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 516,243 while 255,974 shares were sold.